Search results
Results from the WOW.Com Content Network
The Oncotype DX® breast cancer assay is one such test used to predict the likelihood of breast cancer recurrence. This test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor -positive (ER+) invasive breast cancer who will be treated with hormone therapy .
The researchers said their findings, presented at the 13th European Breast Cancer Conference, could “form the basis of blood testing for people with a genetic predisposition or a family history ...
Tumor markers can be molecules that are produced in higher amounts by cancer cells than normal cells, but can also be produced by other cells from a reaction with the cancer. [2] The markers can't be used to give patients a diagnosis but can be compared with the result of other tests like biopsy or imaging. [2]
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention."
More women may benefit from gene testing for hereditary breast or ovarian cancer, especially if they've already survived cancer once, an influential health group recommended Tuesday. At issue are ...
In contrast, mutation of other genes unrelated to the tumor formation may lead to synthesis of abnormal proteins which are called tumor-associated antigens. Other examples include tissue differentiation antigens, mutant protein antigens, oncogenic viral antigens , cancer-testis antigens and vascular or stromal specific antigens.
Inflammatory breast cancer [1] (IBC) is one of the most aggressive types of breast cancer. It can occur in women of any age (and, extremely rarely, in men, see male breast cancer [ 2 ] ). It is referred to as "inflammatory" due to its frequent presentation with symptoms resembling a skin inflammation, such as erysipelas .
MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. [1] It gives a binary result, high-risk or low-risk classification , and helps physicians determine whether or not a patient will benefit from chemotherapy .